Gladwin A M, Martin J F
Cardiovascular Research, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.
Int J Cell Cloning. 1990 Jul;8(4):291-8. doi: 10.1002/stem.5530080414.
Following experimental platelet destruction in animals, large platelets, which are more hemostatically active, are produced before any change in bone marrow megakaryocyte DNA content. When platelet production is stimulated by administration of i.v. vincristine in rats, megakaryocyte ploidy is increased, but mean platelet volume is unchanged. When platelet production and destruction are both stimulated by chronic hypoxia or administration of anti-platelet serum, mean platelet volume and megakaryocyte DNA content are both increased. Since platelet volume is determined primarily at thrombopoiesis, these results imply that mean platelet volume and megakaryocyte DNA content are under separate hormonal control. Therefore, it has been postulated that changes in mean platelet volume occur following changes in platelet production rate, whereas changes in megakaryocyte ploidy are associated with an increased rate of platelet production. In myocardial infarction, platelets have increased mean volume and reduced bleeding time more than in controls. In addition, men with myocardial infarction have increased megakaryocyte size and increased DNA content when compared to controls. These changes are similar to those observed in rabbits following cholesterol feeding. If megakaryocyte polyploidy and mean platelet volume are under separate hormonal control, this suggests that in myocardial infarction, both hormones are active--one stimulating an increased platelet size, the other stimulating the increased megakaryocyte DNA content. In contrast, patients with lymphoma exhibiting a secondary thrombocytosis have no change in mean platelet volume. However, these subjects also have larger bone marrow megakaryocytes when compared to controls. The relation between megakaryocyte size and ploidy implies that the DNA content of these cells is increased in lymphoma.(ABSTRACT TRUNCATED AT 250 WORDS)
在动物实验性血小板破坏后,骨髓巨核细胞DNA含量尚未发生任何变化之前,就会产生止血活性更强的大血小板。当给大鼠静脉注射长春新碱刺激血小板生成时,巨核细胞倍性增加,但平均血小板体积不变。当慢性缺氧或给予抗血小板血清同时刺激血小板生成和破坏时,平均血小板体积和巨核细胞DNA含量均增加。由于血小板体积主要在血小板生成过程中确定,这些结果表明平均血小板体积和巨核细胞DNA含量受不同激素控制。因此,有人推测平均血小板体积的变化发生在血小板生成速率改变之后,而巨核细胞倍性的变化与血小板生成速率增加有关。在心肌梗死患者中,血小板的平均体积增加,出血时间比对照组缩短。此外,与对照组相比,心肌梗死男性患者的巨核细胞大小增加,DNA含量增加。这些变化与喂食胆固醇的兔子中观察到的变化相似。如果巨核细胞多倍性和平均血小板体积受不同激素控制,这表明在心肌梗死中,两种激素都有活性——一种刺激血小板大小增加,另一种刺激巨核细胞DNA含量增加。相比之下,患有继发性血小板增多症的淋巴瘤患者平均血小板体积没有变化。然而,与对照组相比,这些患者的骨髓巨核细胞也更大。巨核细胞大小与倍性之间的关系表明,这些细胞的DNA含量在淋巴瘤中增加。(摘要截取自250字)